Evidence map›Paper›PMID 30143532›Full record

ArticleThe Journal of biological chemistry2018

The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylation-mediated 14-3-3 binding.

James P Madigan, Feng Hou, Linlei Ye, Jicheng Hu, Aiping Dong, Wolfram Tempel, Marielle E Yohe, Paul A Randazzo, Lisa M Miller Jenkins, Michael M Gottesman and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. PHLPP is neither a Phosphatase nor a Tumor Suppressor.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 5 countries.

James P MadiganFrom the Laboratory of Cell Biology.
Feng Houthe Structural Genomics Consortium and.
Linlei YeDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5G 1L7, Canada, and.
Jicheng Huthe Structural Genomics Consortium and.
Aiping Dongthe Structural Genomics Consortium and.
Wolfram Tempelthe Structural Genomics Consortium and.
Marielle E YohePediatric Oncology Branch, and.
Paul A RandazzoLaboratory of Cell and Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892.
Lisa M Miller JenkinsFrom the Laboratory of Cell Biology.ORCID 0000-0003-1245-1338
Michael M GottesmanFrom the Laboratory of Cell Biology, mgottesman@nih.gov.ORCID 0000-0001-8908-2097
Yufeng Tongthe Structural Genomics Consortium and yufeng.tong@uwindsor.ca.ORCID 0000-0001-7740-1812
University of Toronto · CANational Institutes of Health · US

Funding

CPTR - Mass Spectrometry UnitZICBC011430 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JENKINS, LISA · 2012 to 2025
$9.4M
Wellcome Trust
6 · The paper itself

Abstract

The tuberous sclerosis complex (TSC) is a negative regulator of mTOR complex 1, a signaling node promoting cellular growth in response to various nutrients and growth factors. However, several regulators in TSC signaling still await discovery and characterization. Using pulldown and MS approaches, here we identified the TSC complex member, TBC1 domain family member 7 (TBC1D7), as a binding partner for PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1), a negative regulator of Akt kinase signaling. Most TBC domain-containing proteins function as Rab GTPase-activating proteins (RabGAPs), but the crystal structure of TBC1D7 revealed that it lacks residues critical for RabGAP activity. Sequence analysis identified a putative site for both Akt-mediated phosphorylation and 14-3-3 binding at Ser-124, and we found that Akt phosphorylates TBC1D7 at Ser-124. However, this phosphorylation had no effect on the binding of TBC1D7 to TSC1, but stabilized TBC1D7. Moreover, 14-3-3 protein both bound and stabilized TBC1D7 in a growth factor-dependent manner, and a phospho-deficient substitution, S124A, prevented this interaction. The crystal structure of 14-3-3ζ in complex with a phospho-Ser-124 TBC1D7 peptide confirmed the direct interaction between 14-3-3 and TBC1D7. The sequence immediately upstream of Ser-124 aligned with a canonical β-TrCP degron, and we found that the E3 ubiquitin ligase β-TrCP2 ubiquitinates TBC1D7 and decreases its stability. Our findings reveal that Akt activity determines the phosphorylation status of TBC1D7 at the phospho-switch Ser-124, which governs binding to either 14-3-3 or β-TrCP2, resulting in increased or decreased stability of TBC1D7, respectively.

Indexed as

Tuberous Sclerosis14-3-3 Proteinsbeta-Transducin Repeat-Containing ProteinsBinding SitesCarrier ProteinsCrystallography, X-RayHumansIntracellular Signaling Peptides and ProteinsPhosphorylationProtein BindingProtein StabilityProto-Oncogene Proteins c-aktSerineUbiquitination14-3-3 Proteinsbeta-Transducin Repeat-Containing ProteinsCarrier ProteinsIntracellular Signaling Peptides and ProteinsProto-Oncogene Proteins c-aktSerineTBC1D7 protein, human14-3-3 proteinAkt PKBE3 ubiquitin ligasemTORC1phosphorylationphospho-switchprotein stabilitytuberous sclerosis complex (TSC)ubiquitylation (ubiquitination)

Identifiers

PMID30143532
PMCPMC6200923
OpenAlexW2888064284

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.